Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2012 by Penn State University.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Yixing Jiang, Penn State University
ClinicalTrials.gov Identifier:
NCT00565487
First received: November 29, 2007
Last updated: November 30, 2012
Last verified: November 2012

November 29, 2007
November 30, 2012
December 2007
December 2013   (final data collection date for primary outcome measure)
To determine optimal dosage for Capecitabine and Tarceva combination in the setting of radiation. [ Time Frame: Two years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00565487 on ClinicalTrials.gov Archive Site
To assess treatment efficacy and overall survival. [ Time Frame: Two years ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
Phase I Study of Combination of Capecitabine and Erlotinib Concurrent With Radiotherapy in Patients With Non-Operable Locally Advanced Pancreatic Cancer

The primary purpose of this study is to determine the best dosage of Capecitabine and Tarceva combination in the setting of radiation and to assess treatment effectiveness, progression-free survival and overall survival.

Over the past several decades, 5-fluorouracil based chemoradiation has been the cornerstone for the treatment of locally advanced non-operable pancreatic cancer. However, the survival of these patients is disappointing. The majority of the patients suffer either local progression or metastatic disease. With the availability of Capecitabine, a few pilot studies showed the the drug is convenient, tolerable and safe in combination with radiation therapy. Capecitabine demonstrated its superior anti-tumor activity with 14 months of median survival. However, these are small Phase I studies and the survival benefit needs to be further validated with larger studies. Epidermal growth factor receptor (EGFR) has been implicated in tumor growth and angiogenesis. Inhibiting EGFR by Tarceva has demonstrated effective treatment in metastatic pancreatic cancer. Anti-epidermal growth factor therapy in combination with radiotherapy has been demonstrated efficacious in other solid tumors such as head and neck cancer. We hypothesize that the combination of Tarceva and Capecitabine has synergistic anti-tumor effect. Hence, improvement of median survival could be potentially achieved with this novel combination.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Pancreatic Cancer
Drug: Capecitabine, Tarceva
Capecitabine is a self-administered (oral) medication & will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine & Tarceva is continued daily until the completeness of the radiation or toxicity.
Other Names:
  • Capecatine, Xeloda
  • Tarceva, Erlotinib, OSI-774
Experimental: Single arm
This is a single arm dose escalation study with a cohort expansion.
Intervention: Drug: Capecitabine, Tarceva
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
27
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologic or cytologic diagnosis of adenocarcinoma of the pancreas that is locally advanced & not amenable to resection with curative intent.
  • Must not have received prior systemic therapy for locally advanced disease.
  • ECOG performance status must be 0-2.
  • Adequate hepatic, renal & bone marrow function.
  • Radiographic evidence of disease is required.
  • Life expectancy > 12 weeks.

Exclusion Criteria:

  • Prior treatment with Capecitabine & other EGFR inhibitor.
  • Patients with GI tract disease resulting in an inability to take oral medications.
  • Significant GI disorders with diarrhea as a major symptom.
  • Uncontrolled intercurrent illness including active infection,symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias now well controlled with medication, myocardial infarction within the previous 6 months, psychiatric illness/social situations that would limit compliance with study requirements.
  • Patients with metastases.
  • Patients who have had chemotherapy.
  • Patients may not be receiving any other investigational agents, or have participated in any investigational drug study.
  • Extensive symptomatic fibrosis of the lungs.
  • Females who are pregnant or lactating.
  • History of any other malignancy in the last 2 years, except prior history of in situ cancer, basal or squamous cell skin cancer are eligible.
  • Known DPD deficiency.
  • Receiving therapeutic doses of Coumarin-derivative anticoagulant therapy. Patients requiring anticoagulation who may be safely switched to LMWH are eligible.
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00565487
PSU 25709, OSI4058s
Yes
Yixing Jiang, Penn State University
Penn State University
Genentech, Inc.
Principal Investigator: Yixing Jiang, M.D. Penn State College of Medicine
Penn State University
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP